Abstract. The aim of this study was to evaluate the estrogenic activity of tuberous samples of wild, phytoestrogen-rich Pueraria mirifica collected from 28 out of 76 provinces of Thailand by MCF-7 proliferation assay. The plant extracts were administered to MCF-7, ERα positive human mammary adenocarcinoma cell cultures, for 3 days at dosages of 0.1, 1, 10, 100 and 1,000 µg/ml and were compared with 17β-estradiol at concentrations of 10 -12 -10 -6 M. The mean P. mirifica population at 1 µg/ml exhibited significant proliferation. Two plant samples exhibited levels of proliferation in MCF-7 that were similar to 17β-estradiol. The mean P. mirifica populations at 100 and 1,000 µg/ml exhibited significant cytotoxicity in MCF-7. Analysis of the estrogenic activity of puerarin, representative of major isoflavonoids in P. mirifica tubers, revealed proliferation in MCF-7 only at the highest dose (10 -6 M) that was 10 2 -10 5 times less active than 17β-estradiol. Puerarin and 17β-estradiol at concentration of 10 -12 -10 -6 M exhibited no cytotoxicity in MCF-7. Key words: Isoflavonoid, MCF-7 proliferation assay, Phytoestrogen, Pueraria mirifica, Puerarin (J. Reprod. Dev. 54: [63][64][65][66][67] 2008) he plants in genus Pueraria are largely distributed in Asia and have a long history of ethnopharmacological applications [1]. Pueraria mirifica Airy Shaw et Suvatabhandu, family Leguminosae, is an indigenous Thai herb. The potent estrogenic activity of the plant has been proven in a 1-year human clinical trial of 4 menopausal volunteers at Ramathibodi Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand. An average dose of 100 mg of tuberous powder per day was effective for long-term treatment of menopausal symptoms [2], and toxicological tests showed that it did not have significant adverse effects in animals and human volunteers. An acute toxicity test of P. mirifica treatment at a dose of 16 g/kg BW using rats did not reveal any adverse effects [3]. However, P. mirifica did initiate adverse effects such as anemia, during subchronic treatment for 3 months at doses of 100 and 1,000 mg/kg BW [4]. Haemotological adverse effects were confirmed in a 6-month chronic toxicity test at a dose of 250 mg/kg BW [5]. Treatment with the plant extract at high doses 600 and 800 mg/kg BW, for 30 days induces micronucleus formation in male rats [6]. However, pretreatment of weanling rats with P. mirifica powder at a dose of 10, 100 and 1,000 mg/kg BW for 28 days resulted in a dose-dependent prevention of mammary tumors induced by 7, 12-dimethylbenz (a) anthracene (7, 12-DMBA) [7].The phytoestrogens of P. mirifica exhibit the following responses: dose-dependent estrogenic effects on the reproductive system, initiated vaginal cornification, increased uterine weight with decreased follicle stimulating hormone (FSH) and luteinizing hormone (LH) serum levels in ovariectomized rats [8], increased length of the follicular phase and total menstruation cycle [9], decreased estrogen, progesterone, FSH, and LH concentrations at the do...